Haemonetics Reiterated at Outperform With $88 Target and 1 Stock Analysis to Track

Haemonetics Corp. (NYSE:HAE) base business is believed by Barrington to continue to be strong as its integration of PALL is proceeding better than predicted. The firm increased its target on the stock to $88 from $79 yesterday, and it keeps Outperform rating on the stock.